NEWS
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics (NASDAQ: CGTX) has published results from the SEQUEL study of CT1812, their lead candidate for Alzheimer's disease treatment, in The Journal of Prevention of Alzheimer's Disease.
The single-site study measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's after 29 days of treatment. CT1812-treated participants showed consistent trends of improvement across all prespecified EEG parameters, with significant changes in relative theta power and AEC-c, which assesses brain region connectivity.
The study suggests CT1812 may normalize brain wave patterns and facilitate communication between brain regions by protecting synapses as an Aβ oligomer antagonist. Treatment produced a reduction in global relative theta power across various brain regions and improved global alpha AEC-c. CT1812 was well-tolerated with mostly mild to moderate adverse events reported.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1689Followers
93Following
13KVisitors
Follow